CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

214

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/26/18	$0.1394	-5.81%	6,661
14/26/14	$0.1480	+1.40%	840
13/26/13	$0.1460	+10.66%	2,693
12/26/12	$0.1319	+2.41%	1,154
11/26/11	$0.1288	+7.33%	6,252

Real-time OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Real-time OTC Markets 08:27:58 03/06/2026 pm IST			5-day change	1st Jan Change
0.1052 ^USD	-2.09%		-18.25%	-87.61%

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI

Market Cap	28.65L 24.58L 22.95L 21.06L 39.6L 27Cr 40.25L 2.71Cr 1.06Cr 14Cr 1.08Cr 1.05Cr 45Cr	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	2.47Cr 2.12Cr 1.98Cr 1.82Cr 3.42Cr 236.27Cr 3.47Cr 23Cr 9.15Cr 118.5Cr 9.28Cr 9.08Cr 391.8Cr	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
21/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03/03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

14/08	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
01/07	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

CASI Pharmaceuticals, Inc. Share Price

Stocks

CASIF

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	-2.09%
1 week	-18.25%
Current month	-18.25%
1 month	-36.57%
3 months	-24.79%
6 months	-86.48%
Current year	-87.61%

1 week	0.11	0.16
1 month	0.11	0.17
Current year	0.05	1.2
1 year	0.05	2.59
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
18/03/26	Hai Huang	Other	Global Chief Commercial Ofcr	2,80,000	1.8073%
07/09/22	Alexander Zukiwski	Free	Chief Technology Officer	3,000	0.0220%
06/09/22	James Huang	Other	Chairman	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	-2.09%	-18.25%	-95.34%	-95.46%	28.65L
ELI LILLY AND COMPANY	+4.61%	+4.70%	+81.68%	+132.27%	1,09300Cr
JOHNSON & JOHNSON	+1.21%	+5.08%	+54.17%	+63.80%	65TCr
ABBVIE INC.	+2.63%	+6.73%	+28.76%	+76.80%	46TCr
ROCHE HOLDING AG	+1.80%	+0.52%	+41.20%	+44.48%	35TCr
NOVARTIS AG	+1.24%	+2.35%	+25.99%	+41.24%	29TCr
ASTRAZENECA PLC	+2.07%	+2.97%	+2.27%	+12.89%	25TCr
AMGEN INC.	+3.86%	+6.15%	+49.47%	+69.45%	23TCr
NOVO NORDISK A/S	+1.05%	-0.02%	-13.96%	-52.51%	20TCr
GILEAD SCIENCES, INC.	+3.34%	+9.00%	+25.53%	+95.02%	18TCr
Average	+1.95%	+1.08%	+19.98%	+38.80%	37.1TCr
Weighted average by Cap.	+2.74%	+1.45%	+46.81%	+74.01%

	2024	2025
Net sales	2.85Cr 2.45Cr 2.29Cr 2.1Cr 3.94Cr 272.76Cr 4.01Cr 27Cr 11Cr 136.8Cr 11Cr 10Cr 452.3Cr	2.07Cr 1.78Cr 1.66Cr 1.52Cr 2.86Cr 197.97Cr 2.91Cr 20Cr 7.67Cr 99Cr 7.78Cr 7.61Cr 328.28Cr
Net income	-3.93Cr -3.37Cr -3.14Cr -2.89Cr -5.43Cr -375.23Cr -5.51Cr -37Cr -15Cr -188.19Cr -15Cr -14Cr -622.23Cr	-4.81Cr -4.12Cr -3.85Cr -3.53Cr -6.64Cr -459.34Cr -6.75Cr -45Cr -18Cr -230.38Cr -18Cr -18Cr -761.7Cr
Net Debt	60.5L 51.9L 48.46L 44.46L 83.61L 58Cr 84.98L 5.72Cr 2.24Cr 29Cr 2.27Cr 2.22Cr 96Cr	2.19Cr 1.87Cr 1.75Cr 1.61Cr 3.02Cr 208.88Cr 3.07Cr 21Cr 8.09Cr 104.76Cr 8.21Cr 8.03Cr 346.38Cr